-
Company Insights
Innovation and Patenting activity of Agios Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Agios Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AG-946 in Sickle Cell Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AG-946 in Sickle Cell Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AG-946 in Sickle Cell Disease Drug Details: AG-946 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-319 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-319 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-319 in Diffuse Large B-Cell Lymphoma Drug Details: ABBV-319...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Alpha Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitapivat Sulfate in Alpha Thalassaemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mitapivat Sulfate in Alpha Thalassaemia Drug Details: Mitapivat sulfate (Pyrukynd)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mitapivat Sulfate in Acquired (Autoimmune) Hemolytic Anemia Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mitapivat Sulfate in Beta Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mitapivat Sulfate in Beta Thalassaemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mitapivat Sulfate in Beta Thalassaemia Drug Details: Mitapivat sulfate (Pyrukynd)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Chronic Inflammatory Demyelinating Polyneuropathy...
-
Product Insights
Alpha Thalassaemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Alpha Thalassaemia - Drugs In Development, 2023’, provides an overview of the Alpha Thalassaemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alpha Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...